1021346-05-3
Chemical Structure
P4pal10
- CAS No.: 1021346-05-3
- Formula:C65H112N22O13
- Molecular Weight:1409.72
InChIKey: HYVVLYYGZHMEJW-JMDYEWFISA-N
SMILES: OC(C=C1)=CC=C1C[C@@H](C(NCC(N[C@H](C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)=O)=O)CC2=CN=CN2)=O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CO)NC(CCCCCCCCCCCCCCC)=O)=O)=O)=O)=O
Biological Activity: P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
P4pal10 | P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Houle S, et al. Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol. 2005 Nov;146(5):670-8. [Content Brief]
- [2]. Strande JL, et al., Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther. 2008 Mar;324(3):1045-54. [Content Brief]
- [3]. Wielders SJ, et al., Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. J Thromb Haemost. 2007 Mar;5(3):571-6. [Content Brief]
